- Home
- KPTI
as 11-22-2024 4:00pm EST
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
| Founded: | 2008 | Country: | United States |
| Employees: | 325 | City: | NEWTON |
| Market Cap: | 105.9M | IPO Year: | 2013 |
| Target Price: | $5.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.62 - $1.95 | Next Earning Date: | 11-05-2024 |
| Revenue: | $148,442,000 | Revenue Growth: | 1.77% |
| Revenue Growth (this year): | 6.67% | Revenue Growth (next year): | 8.58% |
Stock Insider Trading Activity of Karyopharm Therapeutics Inc. (KPTI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paulson Richard A. | KPTI | President and CEO | Nov 5 '24 | Sell | $0.91 | 3,675 | $3,346.46 | 1,131,932 | |
| Paulson Richard A. | KPTI | President and CEO | Oct 4 '24 | Sell | $0.88 | 3,607 | $3,171.64 | 1,131,932 | |
| Cheng Sohanya Roshan | KPTI | EVP & Chief Commercial Officer | Sep 4 '24 | Sell | $0.72 | 5,356 | $3,865.96 | 404,051 | |
| Paulson Richard A. | KPTI | President and CEO | Sep 4 '24 | Sell | $0.72 | 3,667 | $2,646.84 | 1,131,932 | |
| Mano Michael | KPTI | SVP, General Counsel&Secretary | Sep 4 '24 | Sell | $0.72 | 3,971 | $2,866.27 | 273,881 | |
| Mason Michael | KPTI | EVP, CFO & Treasurer | Sep 4 '24 | Sell | $0.72 | 7,050 | $5,088.69 | 391,054 |
Latest Karyopharm Therapeutics Inc. News
KPTI Breaking Stock News: Dive into KPTI Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Karyopharm Therapeutics Appoints Kristin Abate as Chief Accounting Officer
PR Newswire
4 days ago
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
PR Newswire
6 days ago
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
Simply Wall St.
16 days ago
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Simply Wall St.
18 days ago
Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
18 days ago
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
Motley Fool
19 days ago
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript
Zacks
19 days ago
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
Compare KPTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KPTI Karyopharm Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.